Amedisys Statistics
Total Valuation
Amedisys has a market cap or net worth of $3.19 billion. The enterprise value is $3.55 billion.
| Market Cap | 3.19B |
| Enterprise Value | 3.55B |
Important Dates
The next estimated earnings date is Wednesday, July 24, 2024, after market close.
| Earnings Date | Jul 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Amedisys has 32.68 million shares outstanding. The number of shares has increased by 1.03% in one year.
| Shares Outstanding | 32.68M |
| Shares Change (YoY) | +1.03% |
| Shares Change (QoQ) | +1.05% |
| Owned by Insiders (%) | 2.30% |
| Owned by Institutions (%) | 92.98% |
| Float | 32.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 20.81 |
| PS Ratio | 1.42 |
| Forward PS | 1.33 |
| PB Ratio | 2.93 |
| P/FCF Ratio | 32.58 |
| PEG Ratio | 1.35 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.89, with an EV/FCF ratio of 36.27.
| EV / Earnings | n/a |
| EV / Sales | 1.58 |
| EV / EBITDA | 28.89 |
| EV / EBIT | 54.90 |
| EV / FCF | 36.27 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.44.
| Current Ratio | 1.09 |
| Quick Ratio | 0.99 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | 3.92 |
| Debt / FCF | 4.92 |
| Interest Coverage | 2.03 |
Financial Efficiency
Return on equity (ROE) is -2.00% and return on invested capital (ROIC) is -5.82%.
| Return on Equity (ROE) | -2.00% |
| Return on Assets (ROA) | -1.00% |
| Return on Capital (ROIC) | -5.82% |
| Revenue Per Employee | $118,495 |
| Profits Per Employee | -$1,084 |
| Employee Count | 19,000 |
| Asset Turnover | 1.10 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Amedisys has paid $53.39 million in taxes.
| Income Tax | 53.39M |
| Effective Tax Rate | 162.79% |
Stock Price Statistics
The stock price has increased by +6.83% in the last 52 weeks. The beta is 0.79, so Amedisys's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | +6.83% |
| 50-Day Moving Average | 94.61 |
| 200-Day Moving Average | 93.59 |
| Relative Strength Index (RSI) | 66.81 |
| Average Volume (20 Days) | 499,383 |
Short Selling Information
The latest short interest is 2.31 million, so 7.06% of the outstanding shares have been sold short.
| Short Interest | 2.31M |
| Short Previous Month | 2.36M |
| Short % of Shares Out | 7.06% |
| Short % of Float | 7.21% |
| Short Ratio (days to cover) | 7.19 |
Income Statement
In the last 12 months, Amedisys had revenue of $2.25 billion and -$20.59 million in losses. Loss per share was -$0.64.
| Revenue | 2.25B |
| Gross Profit | 999.37M |
| Operating Income | 145.63M |
| Pretax Income | 32.80M |
| Net Income | -20.59M |
| EBITDA | 122.91M |
| EBIT | 64.68M |
| Loss Per Share | -$0.64 |
Balance Sheet
The company has $120.70 million in cash and $481.82 million in debt, giving a net cash position of -$361.11 million or -$11.05 per share.
| Cash & Cash Equivalents | 120.70M |
| Total Debt | 481.82M |
| Net Cash | -361.11M |
| Net Cash Per Share | -$11.05 |
| Equity (Book Value) | 1.09B |
| Book Value Per Share | 33.30 |
| Working Capital | 41.59M |
Cash Flow
In the last 12 months, operating cash flow was $104.69 million and capital expenditures -$6.80 million, giving a free cash flow of $97.88 million.
| Operating Cash Flow | 104.69M |
| Capital Expenditures | -6.80M |
| Free Cash Flow | 97.88M |
| FCF Per Share | $3.00 |
Margins
Gross margin is 44.39%, with operating and profit margins of 6.47% and -0.91%.
| Gross Margin | 44.39% |
| Operating Margin | 6.47% |
| Pretax Margin | 1.46% |
| Profit Margin | -0.91% |
| EBITDA Margin | 5.46% |
| EBIT Margin | 2.87% |
| FCF Margin | 4.35% |
Dividends & Yields
Amedisys does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.03% |
| Shareholder Yield | -1.03% |
| Earnings Yield | -0.65% |
| FCF Yield | 3.07% |
Analyst Forecast
The average price target for Amedisys is $100.75, which is 3.23% higher than the current price. The consensus rating is "Hold".
| Price Target | $100.75 |
| Price Target Difference | 3.23% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 5, 2006. It was a forward split with a ratio of 4:3.
| Last Split Date | Dec 5, 2006 |
| Split Type | Forward |
| Split Ratio | 4:3 |
Scores
Amedisys has an Altman Z-Score of 3.73 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.73 |
| Piotroski F-Score | 4 |